Free shipping on all orders over $ 500

Apixaban

Cat. No. M1649

All AbMole products are for research use only, cannot be used for human consumption.

Apixaban Structure
Synonym:

BMS-562247-01

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 55  USD55 In stock
1mg USD 25  USD25 In stock
5mg USD 50  USD50 In stock
10mg USD 70  USD70 In stock
50mg USD 130  USD130 In stock
100mg USD 175  USD175 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Apixaban is a direct Human Factor Xa inhibitor with Ki of 0.08 nM. Apixaban prolongs the clotting times of normal human plasma with the concentrations (EC2x) of 3.6 μM, 0.37 μM, 7.4 μM and 0.4 μM in vitro. Apixaban significantly inhibits factor Xa activity with IC50 of 0.22 μM in rabbit ex vivo. In the arteriovenous-shunt thrombosis (AVST), venous thrombosis (VT) and electrically mediated carotid arterial thrombosis (ECAT) rabbit models, Apixaban produces dose-dependent antithrombotic effects with EC50 of 270 nM, 110 nM and 70 nM, respectively.

Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method Platelet aggregation assays
Platelet aggregation was measured in citrated human and rabbit platelet-rich plasma (PRP) in vitro with a platelet aggregometer (Model PAP-4D, BioData, Horsham, PA, USA). PRP was obtained from citrated blood after centrifuging at 250 · g for 6 min. Citrated PRP (250 μL) was mixed with 20 μL of vehicle, DMP802 at 3 μM or apixaban at 1–10 μM, and incubated for 3 min at 37℃. DMP802, a glycoprotein (GP)IIb/IIIa receptor antagonist, was included as a positive control (IC50 = 29 nM against human platelet aggregation response to 10 μM ADP). Peak platelet aggregation was determined after the addition of 20 μL of the agonist (ADP at 10 μM, c-thrombin at 35 nM, and collagen at 10 μg mL)1, final concentration).
Concentrations 1-10 μM
Incubation time 3 min
Animal Experiment
Animal models rat AVST model
Formulation 10% N,N-dimethylacetamide; 30% 1,2-propanediol; 60% water
Dosages 0.03, 0.1, 0.3, 1mg/kg/h
Administration intravenously
Chemical Information
Molecular Weight 459.5
Formula C25H25N5O4
CAS Number 503612-47-3
Solubility (25°C) DMSO 46 mg/mL
Storage Powder -20°C
References

[1] Carter et al. J Thromb Thrombolysis. Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.

[2] Martin et al. Clin Med Insights Cardiol. Safety and efficacy of apixaban in the treatment of atrial fibrillation.

[3] Agrawal et al. Curr Drug Targets. Apixaban: a new player in the anticoagulant class.

[4] Wong PC, et al. J Thromb Haemost. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.

Related Factor Xa Products
Rivaroxaban

Rivaroxaban (Xarelto, BAY 59-7939) is oral direct factor Xa inhibitor with an IC50 value of 2.1nM.

Betrixaban

Betrixaban is a highly potent, selective, and orally efficacious factor Xa inhibitor with IC50 of 1.2 nM(inhibition of Factor 10a).

Edoxaban Tosylate Monohydrate

Edoxaban tosylate monohydrate is a selective factor Xa inhibitor with Ki of 0.561 nM, >10000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant compound.

BMS-740808

BMS-740808 is a highly potent, selective inhibitor of blood coagulation factor Xa (fXa) with Ki with 0.03 nM.

Ozagrel

Ozagrel is a potent and selective thromboxane A2 synthetase inhibitor with an IC50 of 4 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Apixaban, BMS-562247-01 supplier, Factor Xa, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.